50807-71-1Relevant academic research and scientific papers
GEMCITABINE AMPHIPHILE PRODRUGS
-
Paragraph 47, (2019/11/12)
The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid crystalline nanostructured nanoparticles, and uses thereof to treat animals, including humans.
AMPHIPHILE PRODRUGS
-
Page/Page column 0170; 0171; 0172, (2019/06/12)
Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolised to a biologically active agent; and X is selected from the group consisting of R, or up to three R moieties attached to a linker, Y1, Y2 or Y3, wherein R is selected from a group consisting of alkyl, alkenyl, alkynyl, branched alkyl, branched alkenyl, branched alkynyl, substituted alkyl, substituted alkenyl and substituted alkynyl groups and their analogues; Y1 is a linker group which covalently attached to an R group at one site and is attached to A at a further independent site; Y2 is a linker group which is covalently attached to two R groups at two independent sites and is attached to A at a further independent site; and Y3 is a linker group which is covalently attached to three R groups at three independent sites and is attached to A at a further independent site. Self-assembly of the amphiphilic prodrugs into reverse lyotropic phases, particularly hexagonal, cubic and sponge, is disclosed. In preferred embodiments A is dopamine or a 5-fluorouracil prodrug.
Selective Delivery of Cytotoxic Compounds to Cells by the LDL Pathway
Firestone, Raymond A.,Pisano, Judith M.,Falck, J. R.,McPhaul, Michael M.,Krieger, Monty
, p. 1037 - 1043 (2007/10/02)
Cancer cells need cholesterol to make new membrane.They get it either by de novo synthesis or low-density lipoprotein (LDL), or both.Some types of cancer have very high LDL requirements.LDL particles, which circulate in the blood, contain a cholesteryl ester core surrounded by a phospholipid coat containing apoproteins that are recognized by LDL receptors on cell surfaces.After attachment to cells, LDL is endocytosed into lysosomes, where the core is exposed and hydrolyzed.A technique is known whereby LDL can be isolated, its core removed and replaced by a compatible lipophilic substance, and then reconstituted into intact LDL particles that are recognized and internalized by cells in the normal manner.A series of cytotoxic compounds has been synthesized, designed to be compatible with reconstituted LDL, and directed against cancers that copiously internalize LDL.They were evaluated by measuring the toxicity of reconstituted LDL toward test cells bearing LDL receptors.Selectivity was determined by comparison, either with mutant cells with few LDL receptors or with reconstituted methylated LDL (which is not recognized by LDL receptors) on normal cells.Two compounds, 19 and 25, were found that reconstitute well, kill or arrest the test cells at reasonably low concentrations, and are completely selective, suggesting that they are delivered to cells exclusively via the LDL pathway.
